May 19, 2020 | Press Releases
Be The Match BioTherapies will Provide Allogeneic Cellular Source Material to NantKwest for Clinical Trial Addressing Primary Cause of COVID-19 Fatality MINNEAPOLIS, Minn., and EL SEGUNDO, Calif., May 19, 2020 – Be The Match BioTherapies®, an organization offering...
May 18, 2020 | Press Releases
NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute...
May 14, 2020 | Press Releases
Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone Metastatic pancreatic cancer...
Apr 29, 2020 | Press Releases
EL SEGUNDO, Calif., April 29, 2020 – NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May...
Apr 14, 2020 | Press Releases
Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS) Vaccine Vector to...
Mar 19, 2020 | Press Releases
Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab EL SEGUNDO, Calif., March 19, 2020 – NantKwest, Inc. (Nasdaq: NK), a next...
